Format

Send to

Choose Destination
Urologe A. 2016 Aug;55(8):1071-7. doi: 10.1007/s00120-016-0093-6.

[Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].

[Article in German]

Author information

1
Urologische Universitätsklinik Heidelberg, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland. Claudia.Kesch@med.uni-heidelberg.de.
2
Urologische Universitätsklinik Heidelberg, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
3
Abteilung für Radiologie, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland.
4
Universitätsklinik für Urologie, Universität Bern, Bern, Schweiz.
5
Institut für Medizinische Biometrie und Informatik, Heidelberg, Deutschland.
6
Pathologisches Institut der Universität Heidelberg, Universität Heidelberg, Heidelberg, Deutschland.

Abstract

BACKGROUND:

Multiparametric MRI (mpMRI) plays an increasingly important role in prostate cancer (PCa) diagnostics and is recommended in men with previously negative TRUS biopsy. The optimal biopsy method after mpMRI is under discussion.

OBJECTIVE:

Prospective, PIRADS- and START-conform analysis of the relevance of mpMRI and MRI-TRUS fusion biopsy in patients with prior negative TRUS biopsy and comparison of the detection rates of fusion-targeted biopsies (tB) and systematic transperineal saturation biopsies (sB).

MATERIALS AND METHODS:

Between 10/2012 and 09/2015, 287 patients with prior negative TRUS biopsy underwent mpMRI and software-assisted, rigid MRI-TRUS fusion biopsy. In addition to and strictly separated from sB (median cores n = 24), tB (median cores per patient n = 4, per lesion n = 3) were performed in case of suspicious MRI lesions (PIRADS ≥ 2). Both biopsy methods were compared by using McNemar's test.

RESULTS:

Of the 287 patients, 148 (52 %) had positive biopsies. Of these, 108/287 (38 %) had significant PCa (Gleason Score [GS] = 3 + 3 and PSA ≥ 10 ng/ml or GS ≥ 3 + 4) and again 43/287 (15 %) had a GS ≥ 4 + 3 PCa. sB failed to diagnose 8/148 PCa (5.4 %) and 6/108 significant PCa (5.5 %), whereas tB failed to diagnose 48 (32.4 %) PCa (p < 0.0001) and 22 (20.4 %) significant PCa (p = 0.0046). Of the PCa missed by tB, 11  had a GS ≥ 3 + 4 and 5 of these a GS = 4 + 3. On a per patient basis, MRI failed to detect 5 significant PCa, whereby 17 of the significant PCa were missed by fusion-targeted cores alone.

CONCLUSIONS:

In men with unsuspicious MRI (PIRADS < 3), there is a 11 % risk of significant PCa. In case of suspicious MRI lesions, the combination of both biopsy approaches offers maximum tumor detection.

KEYWORDS:

Image fusion; Multiparametic magnetic resonance imaging; Prostate biopsy; Protstate cancer; Re-biopsy

PMID:
27168038
DOI:
10.1007/s00120-016-0093-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center